Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 13/20 | 0.50 |
| ▸ | NSD2 | O96028 | 2/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | EHMT1 | Q9H9B1 | 11/20 | 0.45 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20580903 | 0.89 | EHMT2 (0.50) | EHMT2NSD2FGFR2EHMT1KMT5A | |
| SCHEMBL20580578 | 0.80 | TLR9 (0.48) | GABRG2GABRB3GABRA5 | |
| SCHEMBL20581057 | 0.79 | GABRG2 (0.48) | GABRG2GABRB3GABRA5 | |
| SCHEMBL20580859 | 0.79 | EHMT2 (0.50) | EHMT2NSD2FGFR2EHMT1 | |
| SCHEMBL20581143 | 0.77 | EHMT2 (0.47) | EHMT2NSD2FGFR2EHMT1MET | |
| SCHEMBL28372514 | 0.76 | EHMT2 (0.50) | EHMT2EHMT1SPIN1 | |
| SCHEMBL20581642 | 0.73 | EHMT2 (0.38) | EHMT2NSD2EHMT1GABRG2GABRB3 | |
| SCHEMBL20581126 | 0.73 | EHMT2 (0.46) | EHMT2NSD2FGFR2EHMT1 | |
| SCHEMBL20581223 | 0.72 | GABRG2 (0.40) | EHMT2NSD2GABRG2GABRB3GABRA5 | |
| SCHEMBL6345971 | 0.69 | EHMT2 (0.53) | EHMT2NSD2EHMT1SRCSPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634962-B1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20210371417-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11111243-B2 | Azaindole compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3634962-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-110997671-A | Azaindole compounds as histone methyltransferase inhibitors | 全球血液疗法股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2018226998-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| US-20180354947-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111243-B2 | Azaindole compounds as histone methyltransferase inhibitors | EHMT2, EHMT1, EZH2 | EHMT2 1/4885NSD2 96/4885FGFR2 4843/4885 |
| US-20210371417-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT2, EHMT1, EZH2 | EHMT2 1/4885NSD2 96/4885FGFR2 4843/4885 |
| US-20180354947-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT2, EHMT1, EZH2 | EHMT2 1/4885NSD2 96/4885FGFR2 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.